Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. - Wikidata - awgldk - TriplyDB

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

http://www.wikidata.org/entity/Q33372690

about

Targeting the tumor microenvironment: JAK-STAT3 signaling Screening approaches to generating STAT inhibitors: Allowing the hits to identify the targets 14-3-3ζ interacts with stat3 and regulates its constitutive activation in multiple myeloma cells MPT0B098, a Microtubule Inhibitor, Suppresses JAK2/STAT3 Signaling Pathway through Modulation of SOCS3 Stability in Oral Squamous Cell Carcinoma Therapeutic modulators of STAT signalling for human diseases Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6.CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.The transcriptional modulator BCL6 as a molecular target for breast cancer therapy STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells.Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model.The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.Granulin, a novel STAT3-interacting protein, enhances STAT3 transcriptional function and correlates with poorer prognosis in breast cancer.Targeting the interleukin-6/Jak/stat pathway in human malignancies Tetraspanin CD151 plays a key role in skin squamous cell carcinoma.The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6.Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer.NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma.Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP Combined nifuroxazide and SAT05f therapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis.Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1.Cancer-associated myeloproliferation: old association, new therapeutic target.Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy.STAT signaling in the pathogenesis and treatment of myeloid malignancies.The current management of brain metastasis in melanoma: a focus on riluzole.STAT3 Inhibition by Microtubule-Targeted Drugs: Dual Molecular Effects of Chemotherapeutic Agents.STAT3-Interacting Proteins as Modulators of Transcription Factor Function: Implications to Targeted Cancer Therapy.

P2860

Q26825658-6C9569E3-181E-4EF5-A0FB-7CEE42956777 Q27024482-4245FCA4-9E80-4060-90ED-0F03BCF6A707 Q27310406-E7024A3C-4F44-4418-8387-FE02F13B26EC Q28552305-588D0118-A76D-4580-8A8D-34EA6FF49511 Q33684732-84E746D6-DC1E-4428-B41E-34938E96864B Q33697369-7466FDC7-7692-49DA-ADEE-1B2E270AB797 Q33904846-258B436A-954E-4809-8FB9-8F91F61839B1 Q33934987-780AEB06-AC6A-4BD6-8CC5-1D10443089AA Q33984585-CF759383-5AE4-41EE-A84B-B86E8A69690B Q34194704-9DD80966-1468-44B2-A93F-47859A0690D4 Q34245186-680FD7A9-ECD8-4F46-BD04-F5C3F6D247F9 Q34518047-272563AE-BFAD-4380-97F4-0C4C3793B6E3 Q34754412-1B6FC2C4-AC81-4BDD-BFFD-C351B435D0EE Q34796500-1B799309-62ED-4FFD-848A-DD637DB038FE Q35132241-8F8F3F15-E9D2-41A4-A689-F3836CE1C5C6 Q35165105-4105A411-9871-4C70-8E5A-256400949678 Q35274726-B54CE037-0468-405F-AD48-B7042BF41D91 Q35551777-710F1DD6-2EBA-4CE5-8843-E49EEC6B8F82 Q35591909-3ADC4E83-3962-4852-A23D-57D5F3AD8D9A Q35925127-FC78DA1E-A61B-434C-B186-C3916696A296 Q36350751-8DB458C9-B628-40A2-B9AE-B9A9AC535A50 Q36481950-D3B809D6-A227-4D10-95F7-13D3BB9177CC Q36528249-F67A36CA-C44D-4874-A52D-024C0A181F60 Q36645788-83DE0A68-C23C-4BD6-9FD9-4D58FB16F6AC Q36962588-E8F9F850-C276-4D72-96C4-EA452386F1D6 Q37007610-6D4651E9-F0CF-4019-8A5D-944AE65853D3 Q37036322-C60F664E-4A09-474F-A7FD-6EBBE77BA605 Q37068166-6DA4175C-7E50-49CD-B5A0-94D8A3830202 Q37268717-85C8E132-7CB8-440F-B405-1F52F0EEFE82 Q37309060-45C783EC-E045-40E1-8239-84B237633DC8 Q37411232-3ECC95E8-A480-40F6-B74E-156AB1CB0F0F Q37603497-9E3C44D4-D3E6-464F-A39A-4A6AEE1247C2 Q37744890-5BCC2031-F817-4076-AF6A-73EF31FEB163 Q37745238-306A32FC-ABCD-4AE4-80C9-F9126DD550F6 Q37769017-C6AE115F-C1A7-4720-81CF-FB1868FE5E42 Q37869903-1A0F3F9C-4486-4FC9-9E5E-A20966E86849 Q38140880-E521F99D-9D7B-4FD8-AD5C-DE88321D423D Q38532696-EE1ED00F-864B-46E6-9840-D05334D18264 Q38533925-1D5A1149-6FED-413E-AF9B-F67DA0B11BAA Q38667977-5C9D17E5-9014-42C1-83EA-DCC7F3BF683F

P2860

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

http://www.wikidata.org/entity/Q33372690

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

@ast

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

@en

type

label

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

@ast

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

@en

prefLabel

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

@ast

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

@en

P1433

Q33372690-1364D669-326D-4135-829B-30A58209A49E

P1476

Q33372690-81D96DA5-E7B5-4BB5-BA0C-4BC020A9FE5E

P2093

Q33372690-2D93621C-2A62-4C04-A359-EEEF68F3BB31

Q33372690-36FF4595-1921-483B-8F88-EBE9671FB19E

Q33372690-886D1488-F16B-4CCC-8A56-03E4F54E2C51

Q33372690-95FE3F21-7B05-45C6-8979-91A0BD4C0CD8

Q33372690-ADB66629-6B47-43CA-9A85-5B91166F83C4

Q33372690-DC6FEB56-2DED-4239-83C9-D1B69D57A98E

Q33372690-E9FFA7F4-C660-4ADC-86C3-0371D8282B9E

Q33372690-EA78BF98-8E2D-4296-8F61-25506103C4AB

P2860

Q33372690-11E2D29B-4595-4D31-9916-2323E5FF14DC

Q33372690-1EACD1A8-DD0A-4166-90FD-49524D718FE1

Q33372690-3D8F02C2-0A72-46B2-87AA-969C23F48D43

Q33372690-3EC23795-A55C-4F7E-8485-352F738F722D

Q33372690-4998DBB1-FA1E-4BCB-A529-05689B0F5A35

Q33372690-49D77B4F-DA23-47EB-BEA1-1969800A462F

Q33372690-52375C60-DA5F-4CF4-AECA-57A554DF9163

Q33372690-55AEEEB1-D501-49DA-B692-C509E93B61C5

Q33372690-560AC437-C9BC-4617-A270-DC3B6C7FE3B2

Q33372690-60EB624A-EB4C-4298-956D-A8E11A494321

P304

Q33372690-B23B7966-D9DA-401F-B448-5018A9F16FCF

P31

Q33372690-D46FAF4F-B1F0-4EBD-A4E1-9A551043D401

P356

Q33372690-AC91BB74-9D61-4E1F-9DB7-3855DCACF7F4

P407

Q33372690-1091C9F1-AF7A-41FA-93CA-473CB5252ABC

P433

Q33372690-E0187B6E-8399-4080-90DE-D478FA7E523F

P478

Q33372690-FA5AD4CF-66E6-4A23-A118-EAA985277205

P50

Q33372690-C7E2E7D3-6B32-49CF-8C51-6CEAF8B28C73

P577

Q33372690-95EE32A0-FAE1-4715-BA99-B9A74A135E2D

P5875

Q33372690-D7C03A73-9B7B-4901-9A9C-398234C1E31F

P698

Q33372690-74799165-70CC-49B4-8B70-EDD515BD0032

P932

Q33372690-0A4C39EA-C25E-4AD9-85A3-4C35D941E91B

P356

BLOOD-2007-12-129718

P1433

P1476

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

@en

P2093

Alicia Kepich

http://www.w3.org/2001/XMLSchema#string

David A Frank

http://www.w3.org/2001/XMLSchema#string

Dharminder Chauhan

http://www.w3.org/2001/XMLSchema#string

Erik A Nelson

http://www.w3.org/2001/XMLSchema#string

Hiroshi Ikeda

http://www.w3.org/2001/XMLSchema#string

Laurie B Gashin

http://www.w3.org/2001/XMLSchema#string

Sarah R Walker

http://www.w3.org/2001/XMLSchema#string

Teru Hideshima

http://www.w3.org/2001/XMLSchema#string

P2860

STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas

Histone deacetylase inhibitors in cancer treatment

Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK)

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor

Requirement of serine phosphorylation for formation of STAT-promoter complexes

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

The Jak-STAT pathway.

Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.

[Double-blind controlled study of the efficacy of nifuroxazide versus placebo in the treatment of acute diarrhea in adults]

Jak family of kinases in cancer.

P304

5095-5102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-12-129718

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

P577

2008-09-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23287313

http://www.w3.org/2001/XMLSchema#string

P698

18824601

http://www.w3.org/2001/XMLSchema#string

P932

2597607

http://www.w3.org/2001/XMLSchema#string